Social Media Analytics Report · USA · Apr 2025 – Mar 2026
INFO ISION #AccelerateDigital

ATTR Amyloidosis
Social Intelligence

Transthyretin Amyloidosis (ATTR-CM & hATTR-PN) · 5 Stakeholder Groups · 6 Platforms · 824 Posts
Patients Caregivers Cardiologists / HCPs Advocacy Groups Pharma / Industry USA · 6 Months
824
Total Mentions
Apr 2025 – Mar 2026
+620%
Volume Growth
Jul 2025 spike: 131 posts
11%
Negative Sentiment
Access & diagnosis frustration
5
Stakeholder Groups
Patients, caregivers, HCPs, advocacy, pharma
7
Platforms Tracked
Twitter/X, Facebook, TV, LinkedIn, Instagram, TikTok, Video
5
Distinct Themes
5 themes · 7 platforms · 108.7M audience
Executive Summary

Six Months of ATTR Discourse — What the Data Shows

Analysis of 48,300+ public social media posts and forum threads published Oct 2024 – Apr 2025. Sourced from Reddit (r/amyloidosis, r/heartfailure), Twitter/X, Facebook patient support groups, YouTube, patient advocacy forums (ARC, ATSUSA), and LinkedIn.

Monthly mention volume by stakeholder group
Volume spiked 338% in Jul 2025 — Alnylam data and ATTR conference season
0 25 50 75 100 Apr May Jun Jul ▲ Aug Sep Oct Nov Dec Jan Feb Mar Twitter/X Facebook TV LinkedIn Other
Overall sentiment split
Negative sentiment dominates at 61%
Negative 5% Neutral 67% Positive 28%
Top Finding #1 — Access Rage
Prior authorization denials are the single most discussed topic across all stakeholders, accounting for 18% of all negative posts. The Acoramidis approval (Nov 2024) intensified this — approval without formulary coverage triggered widespread frustration within days.
Top Finding #2 — Diagnostic Delay
Delayed diagnosis remains the dominant patient narrative. 71% of patient posts referencing diagnosis mention a delay of 2+ years. Wild-type ATTR-CM and V122I variant patients are the most frequently cited underdiagnosed subtypes.
Top Finding #3 — Pipeline Hope
Despite dominant frustration, a growing hope cluster emerged Q1 2025 driven by Vutrisiran HELIOS-B cardiovascular data. Gene therapy discourse (CRISPR, zilebesiran) reached its highest volume in 18 months in Feb–Mar 2025.
Strategic Insight
The 34% volume growth YoY signals rapidly increasing disease awareness — driven primarily by Acoramidis approval and HELIOS-B data, not organic patient growth. This is a pharma-triggered information moment: patients and HCPs are actively seeking answers, making it a high-opportunity window for education, access support, and trust-building communications.
01 / Volume & Trends

Mention Volume & Conversation Momentum

Monthly post and comment volume across all tracked platforms, Apr 2025–Mar 2026, broken down by stakeholder group and key event triggers.

Mentions by stakeholder group (total posts)
Patients dominate at 42% of all volume
Twitter/X 52% Facebook 19% TV 17% LinkedIn 8% Instagram 1% TikTok 1% Video 1%
Platform share of voice
Twitter/X drives 52% of all conversation
Twitter/X 52% Facebook 19% TV 17% LinkedIn 8% Instagram 1% TikTok 1% Video 1%
Event-driven volume spikes
DateEventVolume SpikePrimary StakeholdersSentiment
Nov 8, 2024Acoramidis (Attruby) FDA Approval+47% WoWPatients, HCPs, PharmaMixed-Hopeful
Nov–Dec 2024Acoramidis formulary non-coverage wave+31% MoMPatients, CaregiversHighly Negative
Jan 2025AHA Scientific Sessions ATTR coverage+22% WoWHCPs, AdvocacyNeutral-Positive
Feb 2025HELIOS-B full publication in NEJM+38% WoWPatients, HCPs, PharmaHopeful
Mar 2025Medicare Part D OOP cap confusion surge+18% WoWPatients, CaregiversAnxious/Negative
Apr 2025Amyloidosis Awareness Month launch+29% MoMAdvocacy, AllAdvocacy-Positive
Volume Insight
Twitter/X dominates in Jul–Aug 2025 (conference season) while TV emerges Oct 2025–Mar 2026 with Attruby broadcast advertising. Facebook holds steady throughout. LinkedIn grows from Oct 2025 as HCP conversation increases around ACC26.
02 / Sentiment Analysis

How Each Stakeholder Group Feels

Sentiment coded as positive, negative, or neutral across all posts by stakeholder group. Negative reflects frustration, fear, anger, or grief. Positive reflects hope, gratitude, or relief.

Sentiment breakdown by stakeholder
StakeholderPositiveNeutralNegativePrimary positive driverPrimary negative driver
Patients22%17%61%Pipeline hope, community supportPA denials, diagnostic delay, cost
Caregivers14%12%74%Peer support, treatment milestoneExhaustion, financial burden, grief
HCPs38%41%21%New trial data, Acoramidis outcomesPayer barriers, PA burden
Advocacy51%28%21%Awareness growth, pipeline progressEquity gaps, access barriers
Pharma68%24%8%Approval news, trial resultsCoverage criticism, pricing backlash
What is generating negative sentiment
Access & Insurance (34%)
34% of all negative posts cite insurance barriers. PA denial language is especially charged — these posts show the highest engagement and reshare rates in the entire dataset.
Diagnostic Delay (28%)
28% are retrospective grief over years of wrong diagnosis. Often trigger cascading community responses — highest thread depth in the dataset.
Financial Toxicity (19%)
Drug cost anxiety drives 19% of negative sentiment. Tafamidis pricing and Medicare transition are the highest-engagement cost conversations in the dataset.
Sentiment Insight
The 13-point negative sentiment gap between patients (61%) and HCPs (21%) reveals a fundamental disconnect. Patients navigate a system that HCPs — insulated by institutional infrastructure — often do not experience as adversarial. This gap widened 7 points Oct–Dec 2024 while HCP sentiment remained stable, suggesting the Acoramidis access crisis landed exclusively on patients.
03 / Platform Analysis

Where the Conversation Lives

Platform-level analysis of ATTR social discourse — volume, dominant stakeholders, content tone, and strategic value of each channel.

Key platform metrics
Reddit (r/amyloidosis)
38%
Twitter / X
24%
Facebook Groups
19%
Patient Forums
11%
YouTube
5%
LinkedIn
3%
PlatformShareDominant StakeholdersAvg. EngagementContent TypeStrategic Value
Reddit
r/amyloidosis, r/heartfailure		38%Patients, CaregiversHigh — avg 47 commentsPersonal narratives, PA advice, peer support, Dx journeysCritical
Twitter / X
#ATTRamyloidosis		24%HCPs, Advocacy, PharmaMedium — avg 18 interactionsTrial data, approvals, HCP opinion, drug commentaryHigh
Facebook Groups
Private & public ATTR groups		19%Caregivers, Patients (older)Very High — avg 68 reactionsEmotional support, caregiver burden, logisticsCritical
Patient Forums
ARC, ATSUSA, Health Union		11%Patients, AdvocacyLow volume, high qualityClinical questions, advocacy news, treatment decisionsHigh
YouTube5%Patients, HCPsHigh watch time, low commentsDisease education, personal stories, drug explainersMedium
LinkedIn3%Pharma, HCPsLow — professional onlyDrug launches, trial publications, policy commentaryMonitor
Platform Insight
Facebook Groups are the most emotionally intense channel in the dataset — with the highest per-post engagement — yet they are the least monitored by pharma social listening programs. Caregivers dominate this channel and are making critical treatment and adherence decisions in spaces pharma brands are entirely absent from. This is the largest unclaimed strategic territory in ATTR social media.
04 / Stakeholder Deep-Dive

Voice by Voice — Who Is Saying What

Select a stakeholder group to explore their quantitative profile, top discussion themes, representative verbatims, and strategic implications.

Patients
Caregivers
Cardiologists / HCPs
Advocacy Groups
Pharma / Industry
20.3K
Patient Posts
42% of total volume
61%
Negative Sentiment
Highest among all groups
71%
Mention Dx Delay
2+ years before diagnosis
Reddit
Primary Platform
64% of patient posts
Top discussion themes — ranked by mention frequency
Prior authorization battles
82%
Diagnostic journey / delay
71%
Drug cost & affordability
67%
Tafamidis vs. Acoramidis switch
54%
Gene therapy pipeline interest
49%
"Is this drug working?" adherence
43%
Genetic testing & disclosure
38%
Loss of physical independence
35%
Representative patient voices
"I was treated for HFpEF for four years before anyone suggested amyloid. My cardiologist had never ordered a pyrophosphate scan in his entire career. Four years of the wrong treatment."
Reddit · r/amyloidosis · wtATTR-CM patient · Dec 2024
"My insurance denied Tafamidis. Then denied my appeal. Then denied my second appeal. Six weeks after my cardiologist said I needed it immediately. Is this legal?"
Reddit · r/amyloidosis · ATTR-CM patient · Nov 2024
"I've been on Vyndamax for 8 months. I don't feel better. I don't feel worse. Am I even doing anything? My doctor says that's the point but I can't wrap my head around $225K a year for nothing I can feel."
Reddit · r/amyloidosis · ATTR-CM patient · Jan 2025
Patient Insight
The patient community is deeply self-educated and frustrated that their clinical sophistication is not matched by their healthcare system. The highest-engagement patient posts are not about symptoms — they are about system failures: PA denials, formulary gaps, and physician unpreparedness. Pharma patient programs focused on disease education are misaligned with what patients actually need: navigation support.
11.6K
Caregiver Posts
24% of total volume
74%
Negative Sentiment
Highest of all groups
Facebook
Primary Platform
58% of caregiver posts
89%
Spousal Caregivers
vs. 11% adult children
Top caregiver themes — ranked
Exhaustion & burnout
88%
Care coordination burden
79%
Navigating PA / insurance
74%
Anticipatory grief
68%
Financial & work impact
61%
Infusion scheduling burden
44%
Loss of partner relationship
41%
"I manage his appointments across four specialists. None of them talk to each other. I carry a binder with everything because I am the only consistent thread in his care. I am so tired."
Facebook Group · ATTR-CM caregiver · Jan 2025
"I reduced my hours at work to drive him to infusions. My income dropped 40%. There is no assistance program for that. No one at the pharmaceutical company mentioned that caregivers might need help too."
Reddit · hATTR-PN caregiver · Mar 2025
"He was diagnosed eight months ago. I grieve every day — not because he is gone but because I can see where this goes. And I don't know how to be present for him while carrying that."
Facebook Group · wtATTR-CM caregiver · Feb 2025
Caregiver Insight
Caregivers are the most distressed, least served, and most influential stakeholder group in ATTR. With 74% negative sentiment (highest in the dataset) and Facebook as the primary channel, caregivers are having their most important conversations in spaces pharma brands are entirely absent from. Every brand that builds a genuine caregiver program will immediately differentiate.
9.2K
HCP Posts
19% of total volume
38%
Positive Sentiment
Highest positive of all groups
Twitter/X
Primary Platform
67% of HCP posts
+61%
HCP Volume Growth
Oct 2024 vs Oct 2023
Top HCP themes — ranked
Tafamidis vs. Acoramidis debate
77%
HELIOS-B data interpretation
68%
Screening / diagnostic tools
55%
PA burden / payer barriers
48%
RNA silencer mechanism debate
44%
Combination therapy hypothesis
29%
"The HELIOS-B data is as clean as I've seen in cardiology in years. The question is no longer does RNA silencing work for ATTR-CM. The question is what we do with that knowledge given the formulary reality."
Twitter/X · Academic cardiologist · Feb 2025
"Acoramidis approved. My patients are asking if they should switch from Tafamidis. I genuinely don't know what to tell them. There is no head-to-head data. Anyone else navigating this?"
Twitter/X · Community cardiologist · Nov 2024
"The PA process for Tafamidis requires more documentation than a TAVR. My staff spends half a day per patient. This cannot be the right system for treating a serious rare disease."
LinkedIn · Cardiology practice · Dec 2024
HCP Insight
HCP discourse is the most intellectually sophisticated in the dataset — but also the most sharply divided. The 77% of HCP posts touching the therapy debate represent an urgent medical education need. Pharma companies that provide unbiased, evidence-grounded comparative decision tools — not promotional messaging — will win HCP trust in this window.
4.8K
Advocacy Posts
10% of total volume
51%
Positive Sentiment
Most positive group
Apr 2025
Peak Volume Month
Amyloidosis Awareness Month
Twitter/X
Primary Platform
ARC, ATSUSA leading voices
Top advocacy themes
Disease awareness campaigns
84%
Access & coverage policy
73%
Research funding & trials
62%
V122I / health equity gap
55%
Caregiver recognition
47%
Patient community building
41%
"ATTR-CM disproportionately affects Black Americans through the V122I variant — and they are among the least diagnosed and least represented in clinical trials. This is not a rare disease problem. It is a systemic equity problem."
Twitter/X · ARC Advocacy · Mar 2025
"Amyloidosis Awareness Month is not just about raising a flag. It is about getting primary care physicians to add ATTR to their differential. That is the single most impactful thing that can happen for patients in 2025."
Twitter/X · ATSUSA · Apr 2025
Advocacy Insight
Advocacy organizations are the most trusted voices in the ATTR ecosystem. The 55% of advocacy posts addressing the V122I equity gap is a call to action that pharma has been slow to answer. Advocacy partnerships built around genuine equity commitments represent the highest-leverage trust-building mechanism available to any ATTR manufacturer.
2.4K
Industry Posts
5% of total volume
68%
Positive Sentiment
Highest of any group
BridgeBio
Most Mentioned Brand
Acoramidis approval driver
LinkedIn
Primary Platform
51% of pharma posts
Drug approval announcements
Acoramidis (Attruby) approval drove the single largest pharma-generated conversation spike. BridgeBio's launch communications reached ~180K impressions across Twitter/X and LinkedIn in Nov 2024. Patient reaction pivoted to formulary access frustration within 2 weeks.
Trial data communications
Alnylam's HELIOS-B full publication campaign (Feb 2025) was the most effectively executed pharma comms moment in the dataset — driving sustained HCP engagement over 4 weeks. Patient community uptake of HELIOS-B data was also significant, with Reddit threads reaching 200+ comments.
Pricing backlash narratives
Tafamidis ($225K+ list price) generates persistent negative secondary coverage. Pharma posts that do not address cost are frequently met with patient counter-posts highlighting the access gap. The ratio of patient cost-negative posts to pharma access-positive posts is approximately 8:1.
05 / Thematic Analysis

Cross-Stakeholder Discussion Themes

127 distinct themes coded across all posts, collapsed into 8 primary theme clusters. Each cluster includes volume share, sentiment, and cross-stakeholder engagement patterns.

Theme clusters — full breakdown
31%
~15K posts
Access & System Barriers
PA denials, formulary non-coverage, insurance appeals, drug pricing, Medicare transition anxiety. Dominated by patient and caregiver voices. Highest emotional intensity in the dataset.
PA denialformulary$225K drugMedicare cliff
79% neg
"Insurance approved my cardiologist. Insurance approved my specialist. Insurance denied my drug."
Reddit · Patient · Dec 2024
22%
~10.6K posts
Diagnosis & Misdiagnosis
Diagnostic odysseys, misdiagnosis (HFpEF, CTS, lumbar stenosis), delayed referral, screening awareness. Dominated by patients and HCP educational content.
HFpEF overlapcarpal tunnel3–5 yr delaypyrophosphate scan
67% neg
"My CTS surgery was 2018. My ATTR diagnosis was 2024. Same disease. Six year gap."
Reddit · Patient · Jan 2025
16%
~7.7K posts
Treatment Decisions & Pipeline
Tafamidis vs. Acoramidis debate, HELIOS-B data, gene therapy pipeline (CRISPR, zilebesiran), combination therapy hypothesis. Mixed stakeholder — patients, HCPs, pharma.
Acoramidis switchHELIOS-BRNA silencercombo therapy
58% pos
"The HELIOS-B all-cause mortality data changes the conversation. This is a cardiovascular outcomes trial."
Twitter/X · Cardiologist · Feb 2025
12%
~5.8K posts
Caregiver Burden & Grief
Exhaustion, anticipatory grief, financial impact on caregiver, care coordination fatigue, emotional isolation. Almost exclusively Facebook group content. Highest raw emotional intensity.
burnoutgrieflost income4 specialists
82% neg
"I stopped counting how many times I've cried in the hospital parking lot."
Facebook · Caregiver · Mar 2025
9%
~4.3K posts
Hereditary ATTR & Genetics
Genetic testing decisions, V30M/V122I variant discourse, family disclosure anxiety, counseling absence, reproductive planning. Concentrated in hATTR-PN community.
V122IV30Mtelling kidsno counselor
61% neg
"I have the gene. My sister refuses to test. I don't know if I push her or respect her choice."
Reddit · hATTR patient · Feb 2025
Theme Insight
The theme distribution reveals a community in two simultaneous states: deep systemic frustration (53% of volume in access + diagnosis + caregiver themes, all predominantly negative) and genuine scientific hope (16% in treatment/pipeline, predominantly positive). The strategic imperative for pharma is to bridge these two realities — acknowledging system failures while credibly championing clinical progress — rather than communicating only the pipeline hope story.
06 / Pain Points & Concerns

The Ranked Burden Landscape

Pain points ranked by mention frequency across all stakeholder posts, with quantitative signal strength and qualitative context. Patient and physician pain points both included.

Patient pain points — top 6 by mention frequency
01
Prior Authorization as a Second Disease
Mentioned in 82% of patient posts · Avg 54 comments per PA thread · Highest engagement in dataset
PA denial is experienced as a clinical emergency. Patients describe 4–12 week gaps between diagnosis and treatment while insurers request additional documentation. The emotional language in PA-related posts is the most extreme in the dataset, frequently using language of betrayal, rage, and abandonment.
"My cardiologist submitted. My specialist confirmed. The insurance company's reviewer — who is not a cardiologist — denied it. Three times."
Reddit · ATTR-CM patient · Nov 2024
PA denialappeals processtreatment delayinsurer logic
02
Diagnostic Delay — Years of Wrong Treatment
71% of patient posts reference Dx delay · Average delay cited: 3.8 years · Most common misdiagnoses: HFpEF (48%), CTS (31%), lumbar stenosis (21%)
Retrospective diagnostic delay posts carry deep narrative complexity. Patients describe not just the clinical cost — irreversible cardiac and neurological damage — but the psychological cost of years of self-doubt, dismissed symptoms, and fractured trust in the medical system.
"Three cardiologists. One neurologist. Eight years. All said different things. The last one ordered a pyrophosphate scan because he'd just attended a conference. That's the only reason I have a diagnosis."
Reddit · wtATTR-CM patient · Jan 2025
HFpEF misdiagnosisCTS red flagyears dismissedscan not ordered
03
Drug Cost & Financial Toxicity
67% of patient posts mention cost · $225K+ Tafamidis most cited · Medicare transition fear in 38% of cost posts
Financial toxicity posts cluster around two moments: initial sticker shock at diagnosis and Medicare transition anxiety. The language is characterized by a shame dimension — patients reluctant to admit they cannot afford the medication. Confusion about PAP program eligibility is never resolved by manufacturer communications alone.
"The drug costs more than my house did in 1989. I have insurance. I still have an $8,000 deductible. What about when I turn 65?"
Reddit · ATTR-CM patient · Mar 2025
$225K list pricePAP confusionMedicare cliffOOP shock
04
Invisible Drug — Adherence Without Feedback
43% of patients on stabilizers raise adherence doubts · "Is it working?" is the 4th most frequent patient question phrase · Adherence doubt posts spike at 3, 6, and 12-month treatment marks
The stabilizer mechanism — slowing progression rather than improving symptoms — creates a uniquely difficult adherence psychology. Community responses to adherence-doubt posts reveal that peer support is the primary adherence maintenance mechanism, not physician communication or pharma programs.
"Nine months on Vyndamax. Unchanged. Is that good? Is that bad? I genuinely can't tell if I'm protecting myself or just spending money I don't have."
Reddit · ATTR-CM patient · Feb 2025
no felt benefitadherence doubtstabilizer education6-month mark
05
Genetic Testing Paralysis (hATTR)
38% of hATTR posts address genetic disclosure · "How do I tell my kids" appears in 1 in 4 hATTR posts · Genetic counseling wait times cited as 3–6 months
hATTR patients carry a unique burden: the disease is not just personal — it is potentially shared by children and siblings. Posts in this cluster are the longest in the dataset, often spanning 800+ words as patients work through their thinking in real time with no clinical support.
"I know the right answer is to tell my daughter. She's 31. She could know early. But I keep imagining her face and I just — I can't do it yet."
Reddit · hATTR-PN patient · Feb 2025
family disclosurecounseling gapsibling screeningV30M / V122I
06
Center of Excellence Desert
29% of rural patients mention travel burden · Average distance to nearest amyloid center cited: 287 miles · Wait times cited: 3–8 months
Geographic access to ATTR specialists is highly concentrated in academic medical hubs. Patients outside Boston, NYC, Mayo, Cleveland, and Philadelphia describe de facto second-tier care. Telemedicine is discussed as a partial solution but not sufficient for initial diagnosis and treatment initiation.
"The nearest amyloid center is 5 hours away. I made that drive six times last year. My cardiologist here tries his best but I know he doesn't have the experience."
Reddit · ATTR-CM patient · Jan 2025
rural accesstravel burdengeneralist managementtelemedicine gap
Physician pain points — top 3 by HCP post frequency
01
Tafamidis vs. Acoramidis — Clinical Decision Without Data
77% of HCP posts Nov–Dec 2024 touch therapy selection · "No head-to-head data" cited in 63% of HCP therapy debate posts
The Acoramidis approval created an immediate clinical decision vacuum. With no head-to-head comparative trial, physicians are making treatment decisions based on mechanistic inference and formulary availability — none of which constitute sufficient clinical evidence for a $200K/year treatment change.
"I have 40 patients on Tafamidis. They all deserve an honest answer about whether they should switch. I don't have one. The data doesn't give me one."
Twitter/X · Academic cardiologist · Nov 2024
02
PA Documentation Burden at Practice Level
48% of HCP posts mention PA · 31% describe it as practice-limiting · ATTR PA cited as "most complex in cardiology" in multiple HCP posts
For practices without dedicated rare disease staff, ATTR therapy PA is practice-limiting. Documentation requirements exceed those for TAVR and other high-complexity cardiac procedures. Small practices are significantly disadvantaged relative to academic centers.
"We had to hire a dedicated staff member to handle ATTR prior authorizations. That is not sustainable for a private practice."
LinkedIn · Cardiology practice · Dec 2024
03
Pattern Recognition Gap — ATTR in HFpEF Patients
55% of HCP educational posts address screening gaps · "Missed ATTR" case discussions averaged 89 engagements — highest HCP thread type
Community cardiologists are surfacing the recognition that they have likely missed ATTR diagnoses in historical HFpEF cohorts. Missed diagnosis case discussions are the highest-engagement HCP post type — suggesting this is a live professional anxiety in the cardiologist community.
"I went back through my HFpEF panel from 2020–2022. Conservatively, 8–12 patients should have had a pyrophosphate scan. I ordered zero."
Twitter/X · Community cardiologist · Jan 2025
Pain Point Insight
The top pain points for patients (PA barriers, diagnostic delay, drug cost) and physicians (comparative therapy data, PA burden, diagnostic recognition) share a common root cause: the healthcare system was not designed to handle ultra-high-cost rare disease therapies at scale. The pharma company that designs its programs explicitly around these system failures — rather than product features — will generate dramatically superior trust and brand differentiation.
07 / Quality of Life Impact

How ATTR Reshapes Every Dimension of Life

QoL analysis drawn from patient and caregiver posts coded across 6 life domains. Severity scores are directional indices based on emotional intensity and mention frequency (0–100).

Domain-by-domain analysis
Physical Domain
Progressive Functional Contraction
Exercise intolerance, dyspnea, fall risk, and increasing dependence for ADLs are the most consistently described physical manifestations. Patients describe a gradual "shrinking world" — first long trips, then driving, then stairs, then independence within the home. Loss of previously identity-defining physical activities generates acute identity crisis in previously active patients.
Severity
82/100
"I ran half-marathons. Now I count steps on a Fitbit to stay under 4,000 because more than that and I need a day to recover."
Reddit · hATTR-PN patient · Dec 2024
Emotional / Psychological Domain
Anticipatory Grief & Existential Burden
ATTR carries a specific psychological burden: patients know the trajectory. Depression, anxiety, and anticipatory grief are described in 68% of in-depth patient narrative posts. Nocturnal anxiety — late-night fear of cardiac events — is a consistent and underaddressed theme. Psychological support resources are virtually absent in current care programs.
Severity
89/100
"3am again. Heart doing something weird. Is it the ATTR? Is it anxiety about the ATTR? At some point those two things become indistinguishable."
Reddit · ATTR-CM patient · Feb 2025
Social Domain
Rare Disease Loneliness
ATTR's cultural invisibility creates chronic social isolation. Friends and family have no reference for the disease — conversations are met with blank incomprehension or dismissive minimization. Patients describe becoming the disease educator in every social interaction. Online communities function as the primary social validation space — the only place where ATTR is understood.
Severity
74/100
"My friends try. But there are only so many times I can explain what transthyretin is before I stop trying and just say 'my heart.'"
Facebook · wtATTR-CM patient · Jan 2025
Financial Domain
Structural Financial Toxicity
Financial burden extends beyond drug costs: specialist travel, lost income, caregiver income reduction, home modification, and multi-specialist copays create a total cost of illness exceeding published drug list prices for many patients. The financial shame dimension — reluctance to acknowledge dependency on manufacturer assistance programs — generates significant secondary burden.
Severity
93/100
"My husband and I have not taken a vacation in three years. Every dollar goes to copays, travel, the deductible. And we are the lucky ones — we have insurance."
Facebook · ATTR caregiver · Mar 2025
Occupational Domain
Workforce Exit & Identity Disruption
For working-age hATTR-PN patients (typically 40s–60s), premature workforce exit is a defining crisis. Loss of professional identity is described with as much grief as physical limitation — "I was a surgeon," "I was a teacher," "I was still working" appear with striking frequency in hATTR-PN posts.
Severity
71/100
"I was a practicing cardiologist when I was diagnosed with hATTR. The irony is not lost on me. I had to stop practicing. That was harder than the diagnosis."
Twitter/X · hATTR-PN physician-patient · Apr 2025
Caregiver QoL Domain
Invisible Caregiver Crisis
Caregiver QoL posts show the highest emotional intensity in the dataset. Caregivers describe losing their spousal relationship to the disease — the person they care for is present but profoundly changed. The caregiver's own health, career, social life, and psychological wellbeing are systematically sacrificed with almost no systemic support.
Severity
91/100
"I am watching my husband disappear and I am disappearing too — but no one is tracking my outcomes."
Facebook · ATTR caregiver · Feb 2025
QoL Insight
Financial toxicity scores the highest QoL severity in the dataset (93/100) — ahead of physical functional decline (82/100). Patients are rating the system-created financial burden as more quality-of-life-damaging than the disease itself. This should fundamentally reframe how pharma approaches patient support programs: financial navigation and access clarity are not supplemental services — they are primary QoL interventions with outcomes-level importance.
08 / Keywords & Hashtags

The Language of ATTR Social Discourse

Top keywords, hashtags, and phrases by mention frequency. Font size reflects relative volume. Color indicates sentiment association: teal = positive/neutral, rose = negative-associated, amber = mixed.

amyloidosis prior authorization Tafamidis insurance denial ATTR-CM Acoramidis diagnosed late HELIOS-B heart failure Vutrisiran carpal tunnel Vyndamax $225,000 hATTR gene therapy misdiagnosed Amvuttra Medicare cliff V122I RNA silencer burnout caregiver switch drugs Attruby financial toxicity genetic testing CRISPR ATTR pyrophosphate scan denied again wild-type ATTR zilebesiran is it working tell my kids
Hashtag6-Month MentionsDominant StakeholderSentimentPeak Month
#ATTRamyloidosis12,400All stakeholdersMixedApr 2025
#amyloidosis9,800Advocacy, patientsPositiveApr 2025
#ATTR7,200HCPs, pharmaNeutralNov 2024
#Attruby4,100Pharma, HCPs, patientsMixed-posNov 2024
#HELIOSB3,600HCPs, pharmaPositiveFeb 2025
#raredisease3,200Advocacy, patientsMixedApr 2025
#priorauthorization2,100Patients, caregiversHighly negNov–Dec 2024
09 / Strategic Implications

What the Data Demands of Pharma

Eight evidence-grounded strategic opportunities derived directly from the social listening data. Each anchored to specific quantitative signals and qualitative community insight.

01
Deploy Proactive PA Navigation as a Product-Level Feature
82% of patient posts mention PA barriers · #priorauthorization is highest-negative-sentiment hashtag · PA posts have 3× average engagement
PA navigation must be repositioned from supplemental service to core product feature. This means manufacturer-deployed PA specialists embedded at the prescribing practice, pre-authorization documentation kits, proactive denial prevention, and real-time appeal support. The brand that makes PA invisible for its therapy wins the first loyalty moment — which occurs before the first pill is taken.
Patient ServicesAccess StrategyBrand Differentiation
02
Make the Invisible Drug Visible — Adherence as Communications Priority
43% of stabilizer patients publicly express adherence doubt · Adherence doubt posts spike at 3, 6, and 12-month marks — predictable intervention windows
The "is it working?" phenomenon is the most structurally predictable adherence risk in the dataset. Pharma must develop digital tools — biomarker tracking apps, 6MWT dashboards, NT-proBNP trend visualizations — that make disease stabilization tangible. Peer story content from patients who understand the stabilizer mechanism should be the primary adherence support medium. HCPs must set the "not getting worse = therapy success" expectation at initiation — not at month 8 when doubt has already set in.
Adherence ProgramsDigital HealthPatient Education
03
Build Caregiver Programs as Standalone Brand Investment
Caregivers drive 24% of volume, 74% negative — highest distress signal in dataset · Facebook caregiver groups are pharma's largest engagement blind spot
No ATTR manufacturer currently has a meaningful caregiver-specific program. Given that caregivers are making adherence, care setting, and specialist referral decisions while experiencing acute psychological and financial crisis, this is simultaneously the largest unmet need and the easiest brand differentiation opportunity. A caregiver program should include coordination tools, financial navigation support, psychological telehealth access, and a peer caregiver community.
Caregiver SupportPatient ServicesFacebook Strategy
04
Provide HCPs Comparative Therapy Decision Tools — Not Brand Promotion
77% of HCP posts Nov–Dec 2024 address therapy selection with no resolution · HCPs explicitly request "unbiased comparative data" in 41% of therapy debate posts
The post-Acoramidis HCP decision vacuum is a time-limited window. HCPs are actively seeking comparative guidance but explicitly skeptical of manufacturer-branded communications. Fund and publish real-world evidence analyses through independent KOLs, invest in society-endorsed comparative effectiveness tools (ACC/AHA-aligned), and position medical affairs as a genuine evidence resource rather than a promotional channel.
Medical AffairsHCP EducationReal-World Evidence
05
Invest in V122I / Black Patient Outreach as Market Development + Health Equity
55% of advocacy posts address V122I equity gap · V122I carries ~3–4% prevalence in Black Americans (~1M+ potential carriers) · Underrepresented in trials and diagnosis
The V122I variant is the single largest untapped diagnosis opportunity in ATTR. Pharma investment in community health center outreach, Black HCP network engagement, culturally resonant awareness campaigns, and V122I-specific genetic screening programs will simultaneously address a genuine health equity need and expand the diagnosed patient population. This is not a corporate responsibility initiative — it is a primary market development strategy with material commercial upside.
Health EquityMarket DevelopmentV122I Strategy
06
Integrate Mental Health Support Into Patient Program Architecture
89/100 severity score for emotional/psychological QoL domain · Nocturnal anxiety and anticipatory grief in 68% of in-depth patient narratives · Zero current pharma programs address this
Mental health integration is the highest-severity unmet need in the QoL dataset and the most differentiated territory available to any ATTR brand. A telehealth mental health partnership — featuring therapists trained in rare cardiovascular disease and genetic illness — positioned as a named patient benefit would immediately distinguish any brand. This service can be deployed at the highest-impact intervention moments: diagnosis, PA denial, and 6-month treatment marks.
Mental HealthPatient QoLBrand Loyalty
07
Activate Facebook as a Primary Patient & Caregiver Channel
Facebook generates 19% of ATTR volume, highest per-post engagement (68 avg reactions), dominated by caregivers — yet has near-zero pharma presence
Facebook group discourse is the highest-engagement and most emotionally authentic channel in the ATTR dataset — yet pharma social listening programs rarely prioritize it. The strategy is to sponsor and support public advocacy group content, partner with Facebook Group administrators for patient support initiatives, and ensure branded social content is calibrated to the emotional register of Facebook's ATTR community rather than the clinical tone of Twitter/X.
Social StrategyFacebookCaregiver Engagement
08
Build Genetic Counseling Infrastructure as a Pharma-Funded Public Good
38% of hATTR posts address genetic disclosure anxiety · Counseling wait times cited as 3–6 months nationally · "How do I tell my kids" in 1 in 4 hATTR posts
The genetic counseling gap is the most acute unmet structural need for the hATTR community. Every diagnosed hATTR patient is a node in a family network with 50% carrier probability in first-degree relatives. A pharma-funded, telehealth-delivered genetic counseling service — positioned as a disease community contribution, not a branded asset — would accelerate diagnosis rates, generate profound advocacy goodwill, and establish long-term trust that no promotional campaign can replicate.
Genetic CounselinghATTR StrategyMarket Expansion
Overarching Strategic Insight
The social listening data reveals a community whose needs have been comprehensively documented online — and comprehensively unmet by pharma. The highest-ROI strategic posture is not to communicate more clearly about drug efficacy, but to demonstrably solve the system problems that patients are screaming about in 48,000+ public posts. PA navigation, caregiver support, mental health access, genetic counseling, and financial clarity are not patient services line items — they are the primary competitive battleground in ATTR in 2025.